AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7588175 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs
Number of subjects: 0
Study 7588175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 7588175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of antidepressants
Number of subjects: 0
Study 3407609 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg beta-carotene
Number of subjects: 0
Study 3407609 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg beta-carotene
Number of subjects: 0
Study 3407609 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 0
Study 3407609 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg beta-carotene (daily dosing)
Number of subjects: 0
Study 3407609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological doses of beta-carotene (45 and 90 mg)
Number of subjects: 0
Study 764997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent vaccine (measles, mumps, rubella)
Number of subjects: 900
Study 764997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 31492048 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Healthy Primary School of the Future (HPSF)
Number of subjects: 1676
Study 31492048 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Healthy Primary School of the Future (HPSF)
Number of subjects: 1676
Study 31492048 — intervention group
Group type: COMPARATOR
Intervention: Control Schools
Number of subjects: 1676
Study 28289865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimasertib tablet (3 × 20 mg, PO QD)
Number of subjects: 38
Study 28289865 — intervention group
Group type: COMPARATOR
Intervention: Pimasertib capsule (2 × 30 mg, PO QD)
Number of subjects: 38
Study 28289865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease control rate
Number of subjects: 38
Study 25861647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance spectroscopy measurement after thoracentesis
Number of subjects: 45
Study 25861647 — intervention group
Group type: COMPARATOR
Intervention: Bioelectrical impedance spectroscopy measurement before thoracentesis
Number of subjects: 45
Study 23478893 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose protocol (group A)
Number of subjects: 100
Study 23478893 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose protocol (group B)
Number of subjects: 100
Study 23478893 — intervention group
Group type: COMPARATOR
Intervention: LC-AS, HC-AS, and LC-FBP
Number of subjects: 100
Study 21609974 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 761
Study 21609974 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 761
Study 18082504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3491
Study 18082504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3491
Study 18082504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonemergent PCI
Number of subjects: 3491
Study 21320171 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform switching with a 3.3 mm diameter abutment on test implants
Number of subjects: 25
Study 21320171 — intervention group
Group type: COMPARATOR
Intervention: Control implant with a straight 4 mm diameter abutment
Number of subjects: 25
Study 21320171 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test and control implants
Number of subjects: 25
Study 21320171 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal bone-level changes over time
Number of subjects: 25
Study 21320171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial contamination in implants
Number of subjects: 25
Study 15997246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet and exercise intervention
Number of subjects: 507
Study 15997246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 507
Study 15997246 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'UTR Del/Del genotype
Number of subjects: 507
Study 12394419 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25, 0.50, 0.75 mg)
Number of subjects: 28
Study 12394419 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (5, 10, 15 mg)
Number of subjects: 28
Study 12394419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12394419 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 28
Study 12394419 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 28
Study 9869282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by two IMZ implants (group A)
Number of subjects: 60
Study 9869282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by four IMZ implants (group B)
Number of subjects: 60
Study 8041168 — intervention group
Group type: COMPARATOR
Intervention: Mechanical valve (Bjork‐Shiley spherical disc)
Number of subjects: 66
Study 8041168 — intervention group
Group type: COMPARATOR
Intervention: Bioprosthetic valve (Hancock porcine heterograft)
Number of subjects: 66
Study 8041168 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 66
Study 8041168 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention and antibiotics
Number of subjects: 66
Study 8041168 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 66
Study 8041168 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endocarditis
Number of subjects: 66
Study 8041168 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalvular disease surgery
Number of subjects: 66
Study 8041168 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial wound infection
Number of subjects: 66
Study 2924744 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 17
Study 2924744 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-vinyl GABA (GVG)
Number of subjects: 17
Study 162669 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 25 mg t.i.d.
Number of subjects: 50
Study 162669 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg t.i.d.
Number of subjects: 50
Study 162669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30889044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-Aortic Balloon Pump (IABP) therapy
Number of subjects: 600
Study 30889044 — intervention group
Group type: EXPERIMENTAL
Intervention: SelP levels above the 75th percentile at day 3 following AMI
Number of subjects: 600
Study 30889044 — intervention group
Group type: EXPERIMENTAL
Intervention: SelP levels
Number of subjects: 600
Study 29538790 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review intervention (Haight Structured Life Review with modified guiding questions and memory prompts)
Number of subjects: 74
Study 29538790 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing home care (control group)
Number of subjects: 74
Study 27502326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine 60 mg/10 mg
Number of subjects: 143
Study 27502326 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan 60 mg
Number of subjects: 143
Study 24939043 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 36
Study 24939043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22874682 — intervention group
Group type: EXPERIMENTAL
Intervention: graft + laparoscopic Nissen fundoplication
Number of subjects: 24
Study 22874682 — intervention group
Group type: COMPARATOR
Intervention: laparoscopic Nissen fundoplication alone
Number of subjects: 24
Study 20471543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 63
Study 20471543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 63
Study 18331278 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocrisy condition (delivered a speech on dangers of smoking)
Number of subjects: 0
Study 18331278 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocrisy condition (wrote a passage about healthy lifestyle)
Number of subjects: 0
Study 18331278 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 15634953 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PV)
Number of subjects: 383
Study 15634953 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (CV)
Number of subjects: 383
Study 11913801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 microg kg(‐1) min(‐1))
Number of subjects: 28
Study 11913801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10352852 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 10352852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis
Number of subjects: 0
Study 10352852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical standards and independent data monitoring
Number of subjects: 0
Study 10352852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian statistical methods
Number of subjects: 0
Study 7490601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish oil supplementation for 3 months
Number of subjects: 395
Study 7490601 — intervention group
Group type: COMPARATOR
Intervention: Heterogeneous dietary control oils
Number of subjects: 395
Study 2149044 — intervention group
Group type: EXPERIMENTAL
Intervention: teicoplanin plus ciprofloxacin
Number of subjects: 80
Study 2149044 — intervention group
Group type: COMPARATOR
Intervention: gentamicin plus piperacillin
Number of subjects: 80
Study 463800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed protein intake
Number of subjects: 4
Study 463800 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent energy provision
Number of subjects: 4
Study 31813633 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 10 mg
Number of subjects: 931
Study 31813633 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 25 mg
Number of subjects: 931
Study 31813633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 931
Study 29288478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryobiopsy (CB)
Number of subjects: 0
Study 29288478 — intervention group
Group type: COMPARATOR
Intervention: Forceps biopsy
Number of subjects: 0
Study 26357703 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) 0.1 mL topically applied to soft tissues surrounding implants
Number of subjects: 5
Study 26357703 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment applied)
Number of subjects: 5
Study 23351812 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 6 weeks
Number of subjects: 1400
Study 23351812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w injection for 3 months
Number of subjects: 1400
Study 23351812 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety of immunomodulatory treatment
Number of subjects: 1400
Study 23351812 — intervention group
Group type: COMPARATOR
Intervention: Placebo for oral prednisolone
Number of subjects: 1400
Study 23351812 — intervention group
Group type: COMPARATOR
Intervention: Placebo for Mycobacterium w injection
Number of subjects: 1400
Study 21076814 — intervention group
Group type: EXPERIMENTAL
Intervention: flexion
Number of subjects: 147
Study 21076814 — intervention group
Group type: EXPERIMENTAL
Intervention: flexion and compression
Number of subjects: 147
Study 21076814 — intervention group
Group type: EXPERIMENTAL
Intervention: compression
Number of subjects: 147
Study 21076814 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 147
Study 19247497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural analgesia and neuraxial anesthesia (epidural group)
Number of subjects: 494
Study 19247497 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioid analgesia and general anesthesia (IV group)
Number of subjects: 494
Study 19247497 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 494
Study 19247497 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment rate
Number of subjects: 494
Study 17298428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% ointment once daily
Number of subjects: 265
Study 17298428 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.03% ointment twice daily
Number of subjects: 265
Study 17298428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate 0.1% ointment
Number of subjects: 265
Study 17298428 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 265
Study 12649058 — intervention group
Group type: EXPERIMENTAL
Intervention: Move It Groove It intervention
Number of subjects: 1045
Study 12649058 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1045
Study 10918715 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal transit for liquid bolus
Number of subjects: 58
Study 10918715 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying time (T50)
Number of subjects: 58
Study 8809580 — intervention group
Group type: EXPERIMENTAL
Intervention: Portocaval shunt
Number of subjects: 15
Study 8809580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugiura procedure
Number of subjects: 15
Study 1430968 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin
Number of subjects: 122
Study 1430968 — intervention group
Group type: COMPARATOR
Intervention: nalidixic acid
Number of subjects: 122
Study 2996332 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 to 20 mg bid)
Number of subjects: 39
Study 2996332 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 to 50 mg bid)
Number of subjects: 39
Study 2996332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Enalapril + Hydrochlorothiazide)
Number of subjects: 39
Study 31540535 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory nutrition education sessions (group EDU)
Number of subjects: 79
Study 31540535 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory nutrition education sessions with mobile food application (group EDU + APP)
Number of subjects: 79
Study 31540535 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 79
Study 30017276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor group (n=10)
Number of subjects: 50
Study 30017276 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 50
Study 30017276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 26365930 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaLase
Number of subjects: 50
Study 26365930 — intervention group
Group type: COMPARATOR
Intervention: NeoSoniX
Number of subjects: 50
Study 24176534 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy (SET)
Number of subjects: 156
Study 24176534 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (MED)
Number of subjects: 156
Study 24176534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 156
Study 22749221 — intervention group
Group type: EXPERIMENTAL
Intervention: PICSI
Number of subjects: 100
Study 22749221 — intervention group
Group type: COMPARATOR
Intervention: Sperm Slow
Number of subjects: 100
Study 19835829 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg H5N1 with 50% MF59
Number of subjects: 753
Study 19835829 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of MF59 with various antigen levels
Number of subjects: 753
Study 19835829 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations
Number of subjects: 753
Study 19835829 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of vaccine
Number of subjects: 753
Study 17889386 — intervention group
Group type: EXPERIMENTAL
Intervention: Late course accelerated fractionated (LCAF) radiotherapy
Number of subjects: 178
Study 17889386 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation radiotherapy
Number of subjects: 178
Study 15892593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0
Study 12456612 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH + LH
Number of subjects: 2
Study 12456612 — intervention group
Group type: COMPARATOR
Intervention: FSH alone
Number of subjects: 2
Study 9821828 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia
Number of subjects: 302
Study 9821828 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Number of subjects: 302
Study 9821828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 9821828 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea treatments
Number of subjects: 302
Study 7522003 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser
Number of subjects: 141
Study 7522003 — intervention group
Group type: COMPARATOR
Intervention: Krypton red laser
Number of subjects: 141
Study 2475392 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endoprosthesis
Number of subjects: 50
Study 2475392 — intervention group
Group type: COMPARATOR
Intervention: Operative bypass surgery
Number of subjects: 50
Study 331937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 54
Study 331937 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 54
Study 331937 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 54
Study 331937 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl guaiacolate
Number of subjects: 54
Study 331937 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 54
Study 331937 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 54
Study 30420171 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss intervention with guidance for 0.5 to 1 kg/week weight-loss via energy restriction and aerobic exercise.
Number of subjects: 32
Study 30827784 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen single blastocyst transfer
Number of subjects: 1650
Study 30827784 — intervention group
Group type: COMPARATOR
Intervention: Fresh single blastocyst transfer
Number of subjects: 1650
Study 30110685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 26585525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/SAL)
Number of subjects: 2141
Study 24636673 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 20332
Study 24636673 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus extended-release dipyridamole
Number of subjects: 20332
Study 24636673 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 20332
Study 24636673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20332
Study 22248661 — intervention group
Group type: EXPERIMENTAL
Intervention: FPSA
Number of subjects: 145
Study 22248661 — intervention group
Group type: COMPARATOR
Intervention: SMT
Number of subjects: 145
Study 19408640 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 72
Study 19408640 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy with bipolar diathermy coagulation
Number of subjects: 72
Study 17642235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (humanized anti-human IL-6 receptor antibody)
Number of subjects: 0
Study 15080023 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine hydrochloride at a titrated dose of 10-15 mg once daily for 8 weeks
Number of subjects: 40
Study 15080023 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine hydrochloride
Number of subjects: 40
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: Educative intervention for primary care physicians about dyslipidaemia management.
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic therapy
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA-reductase inhibitors
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibric-acid derivates
Number of subjects: 705
Study 11262334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (after intervention)
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet management only
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibric-acid derivates management
Number of subjects: 705
Study 11262334 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG-CoA-reductase inhibitors management
Number of subjects: 705
Study 9741499 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage angiography
Number of subjects: 201
Study 9741499 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 201
Study 8042733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular morphine 2 mg in 40 ml of normal saline
Number of subjects: 33
Study 8042733 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 2 mg in 1 ml of normal saline
Number of subjects: 33
Study 3172799 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit of fresh whole blood
Number of subjects: 27
Study 3172799 — intervention group
Group type: COMPARATOR
Intervention: 10 units of platelet concentrates
Number of subjects: 27
Study 3172799 — intervention group
Group type: COMPARATOR
Intervention: 8 units of platelet concentrates
Number of subjects: 27
Study 1429339 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) consisting of topical polymyxin E, tobramycin, and amphotericin B administered throughout the unit stay together with parenteral ceftazidime for the first three days.
Number of subjects: 91
Study 1429339 — intervention group
Group type: COMPARATOR
Intervention: Historical control group treated conventionally.
Number of subjects: 91